T he pathogenesis of AML is characterized by serial acquisition of somatic mutations and several genes are recurrently mutated in AML [1] [2] [3] . However, it is not known when such mutations appear prior to the development of overt disease, how they evolve and the specific risk associated with each one. Furthermore, the acquisition of AML-associated mutations has also been found in normal aging, and approximately 10% of people older than 65 years of age 4-7 have clonal hematopoiesis. The presence of clonal hematopoiesis is associated with an increased risk of hematologic malignancies and cardiovascular disease. However, studies of clonal hematopoiesis to date have included very few subjects who subsequently developed AML. Whole-exome sequencing on peripheral blood samples from 17,182 individuals was preformed in a previous study 5 . Mutations in genes that are associated with hematologic cancers were found in 5.6% of subjects aged 60-69 years and in up to 18.4% of those aged > 90 years. Only 16 hematologic cancers were reported in this group, of which 6 were cases with AML. In another study 4 , DNA sequencing was performed on peripheral blood from 12,380 Swedish individuals (mean age, 55 years), with clonal mutations detectable most commonly in DNMT3A, ASXL1 and TET2. Clonal hematopoiesis was strongly associated with increased risk of hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8-28.7), but there were only 12 cases with AML reported in the study 4 . The objective of the present work was to establish a genomically defined premalignant state of AML and ascertain the premalignant mutational landscape of AML years before the diagnosis of the disease. We further sought to investigate whether specific mutations, allele burdens or patterns of coexisting mutations would affect the risk and time-to-diagnosis of AML. To this end, we performed deep sequencing of serially collected peripheral blood samples obtained from 212 women a median of 9.6 years before their diagnosis of AML, along with 212 age-matched controls.
T he pathogenesis of AML is characterized by serial acquisition of somatic mutations and several genes are recurrently mutated in AML [1] [2] [3] . However, it is not known when such mutations appear prior to the development of overt disease, how they evolve and the specific risk associated with each one. Furthermore, the acquisition of AML-associated mutations has also been found in normal aging, and approximately 10% of people older than 65 years of age [4] [5] [6] [7] have clonal hematopoiesis. The presence of clonal hematopoiesis is associated with an increased risk of hematologic malignancies and cardiovascular disease. However, studies of clonal hematopoiesis to date have included very few subjects who subsequently developed AML. Whole-exome sequencing on peripheral blood samples from 17,182 individuals was preformed in a previous study 5 . Mutations in genes that are associated with hematologic cancers were found in 5.6% of subjects aged 60-69 years and in up to 18 .4% of those aged > 90 years. Only 16 hematologic cancers were reported in this group, of which 6 were cases with AML. In another study 4 , DNA sequencing was performed on peripheral blood from 12,380 Swedish individuals (mean age, 55 years), with clonal mutations detectable most commonly in DNMT3A, ASXL1 and TET2. Clonal hematopoiesis was strongly associated with increased risk of hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8-28.7), but there were only 12 cases with AML reported in the study 4 . The objective of the present work was to establish a genomically defined premalignant state of AML and ascertain the premalignant mutational landscape of AML years before the diagnosis of the disease. We further sought to investigate whether specific mutations, allele burdens or patterns of coexisting mutations would affect the risk and time-to-diagnosis of AML. To this end, we performed deep sequencing of serially collected peripheral blood samples obtained from 212 women a median of 9.6 years before their diagnosis of AML, along with 212 age-matched controls.
Results
Study population and samples. The Women's Health Initiative (WHI) was a large, prospective clinical trial and observational study of more than 160,000 women initiated by the US National Institutes of Health (NIH) in 1991 and consisted of three clinical trials and an observational cohort designed to assess the impact of hormonal therapy on postmenopausal health issues in women with an average follow-up of 10.8 years (s.d., 3.3 years) 8, 9 . Detailed clinical data regarding medical history, medications and complete blood counts were available at baseline assessment. New diagnoses were updated in follow-up, with central confirmation of all new diagnoses of cancer. The participants in the clinical trials were followed at baseline and three, six and nine years after study entry, whereas the participants of the observational cohort were followed at baseline, one and three years after study entry. In addition, all participants of the observational cohort filled out yearly questionnaires for the first eight years of follow-up, updating any new medical diagnoses during follow-up.
Identification of cases.
In the WHI cohort, 212 study participants eventually developed pathologically confirmed AML. Of these, baseline peripheral blood DNA at study entry was available and passed quality control in 188 participants; these were identified as cases to be included in the final analyses. Additional follow-up samples for 130 cases were available at one and/or three years after baseline, all prior to the diagnosis of AML. Exclusion criteria for cases included known diagnosis of any hematological disorder (myeloid and lymphoid), including AML, prior to WHI baseline evaluation.
Controls. Age-matched controls (n = 212) were selected from participants who were confirmed not to have a diagnosis of AML while being followed during the WHI study. Exclusion criteria included concurrent or history of prior hematologic disorder (myeloid and lymphoid), including AML, at WHI baseline. Controls were matched to cases by age at baseline within two years, history of nonhematologic cancers at baseline and type and timing of any cancers that occurred in cases after WHI baseline, but before the diagnosis of AML as well as the exact timing of blood sample collection and follow up in the WHI. Matching was done in a time forward manner to ensure that each control had as much control time as its matched case 10 . Of the 212 controls, peripheral blood was available and passed quality standard in 181 controls at WHI baseline and these were included in the analyses. Additional follow up samples for 126 controls were available at one and/or three years after baseline.
Landscape of mutations in blood before aML diagnosis
With a median of 9.6 years before diagnosis of AML, cases were more likely to harbor mutations than controls (odds ratio, 4.86; 95% confidence interval, 3.07-7.77; P = 3.8 × 10
−13
). The most common mutations identified above 1% variant allele fraction (VAF) included DNMT3A (36.7% of cases compared to 18.8% of controls), TET2 (25.0% of cases compared to 5.5% of controls), TP53 (11.2% of cases compared to 0% of controls), SRSF2 (6.9% of cases compared to 0% of controls), IDH2 (6.4% of cases compared to 0% controls), SF3B1 (5.9% of cases compared to 1.1% of controls), JAK2 (5.3% of cases compared to 0.6% of controls) and ASXL1 (3.2% of cases compared to 3.3% of controls; Fig. 1a, Supplementary Fig. 2 and Supplementary Table 2 ). Spliceosome mutations in SF3B1, SRSF2 and U2AF1 were identified as a group in 13.8% of cases (n = 26 out of 188) compared to 1.1% of controls (n = 2 out of 181). Similarly, IDH mutations as a group (both IDH1 and IDH2) were identified in 8% of cases (n = 15 out of 188) compared to 0% of controls. There was no association between the presence of any mutation and abnormal hemoglobin, white-blood cell count and/or platelet level (Supplementary Table 1) . We were not able to evaluate the relationship between red cell distribution width (RDW), absolute neutrophil count and mean corpuscular volume (MCV) with mutations as the WHI did not collect these data.
Overall, cases with AML demonstrated greater clonal complexity than controls, and 46.8% of the cases with AML showed comutations, compared to 5.5% of controls (odds ratio, 9.01; 95% confidence interval, 4.1-21.4; P = 9.7 × 10
−10
). As shown in Fig. 1b , the most common comutations present in cases with AML were DNMT3A with TET2, DNMT3A with SRSF2, TET2 with SRSF2, and IDH2 with SRSF2. Among controls, mutations were generally present individually. When tested for mutual exclusivity and co-occurrence patterns, mutations in DNMT3A, TP53, TET2 and ASXL1 had a tendency toward mutual exclusivity. Conversely, co-occurrence was noted for IDH2 and SRSF2 as well as RUNX1 and PHF6. Among controls, no common co-occurrence pattern was identified and DNMT3A with TET2 was found to be mutually exclusive ( Supplementary Fig. 3 ). Overall, cases with AML had a median of one mutated gene (median, 1; range, 0-8), whereas controls had median of no mutated genes (median, 0; range, 0-2) (P < 2.2 × 10
−16
). Older individuals (≥ 65 years) had more mutated genes in both cases and controls. The same held true for mutations categorized as pathogenic versus variant of unknown significance (Fig. 1c) . We also found that the incremental increase in the number of mutations increased age-adjusted odds of AML per mutation (odds ratio, 3.27; 95% confidence interval, 2.47-4.45).
Presence of mutations at baseline increases risk of aML
Having a mutation at baseline assessment was associated with statistically increased odds of developing AML (odds ratio, 4.86; 95% confidence interval, 3.07-7.77; P = 3.8 × 10 −13 ) ( Table 1 ). This finding was independent of age: odds ratio of 4.39 (2.08-9.61) for cases aged < 65 years; odds ratio of 6.19 (3.25-12.14) for cases aged ≥ 65 years. Overall, 68.62% (n = 129) of cases and only 30.9% of controls (n = 56) were found to have mutations. Mutations were found in 53.75% of cases and 20.78% of controls < 65 years old, and in 79.63% of cases and 38.46% of controls who were ≥ 65 years old. This rate of clonal hematopoiesis in the control group is generally higher than previous reports 4, 5, 11 , which were performed using lowcoverage whole-exome sequencing and a higher VAF cutoff. We therefore also determined the clonal hematopoiesis rate using previous variant classification and VAF cutoff criteria ( Supplementary  Fig. 4 and Supplementary Table 4 ). When performing this adjustment, the observed rate of clonal hematopoiesis in controls was more in line with previous studies at around 7% ( Supplementary  Fig. 4 and Supplementary Table 4 ).
Among the recurrently mutated genes, some mutations demonstrated increased specificity and penetrance for the development of AML. All participants with mutations in TP53 (n = 21 out of 21), IDH1 or IDH2 (n = 15 out of 15), or RUNX1 with PHF6 (n = 3 out of 3) in our cohort eventually developed AML. Multivariable analysis was performed to evaluate potential associations between individual mutated genes and the development of AML, adjusting for confounders including comutated genes and age (Fig. 2a) . This analysis found that TP53 (odds ratio, 47.2; 95% confidence interval, 2.5-879.1), IDH (including IDH1 and IDH2) (odds ratio, 28.5; 95% confidence interval, 1.4-562.8), spliceosome genes (including SF3B1, SRSF2 and U2AF1) (odds ratio, 7.4; 95% confidence interval, 1.7-32.2), TET2 (odds ratio, 5.8; 95% confidence intreval, 2.6-12.9) and DNMT3A (odds ratio, 2.6; 95% confidence interval, 1.5-4.5) were associated with significantly increased odds of developing AML relative to controls and will be referred to as 'high-risk genes' hereafter. Similar results were obtained when considering only those variants flagged as 'likely pathogenic' (Supplementary Fig. 16 ). Study participants who had more than one variant in DNMT3A or TET2 demonstrated significantly increased odds of AML ( Fig. 2b) : two or more DNMT3A variants (odds ratio, 12.6; 95% confidence interval, 3.0-52.9), one DNMT3A variant (odds ratio, 2.1; 95% confidence interval, 1.2-3.8); two or more TET2 variants (odds ratio, 69.3; 95% confidence interval, 3.8-1,280.7), one TET2 variant (odds ratio, 3.29; 95% confidence interval, 1.4-7.8). Because single mutations in DNMT3A and TET2 were the most commonly found mutations in controls, this finding distinguishes the pattern of DNMT3A and TET2 mutations in cases compared to controls. Mutations in IDH1 and IDH2 were exclusively found in the known recurring hotspots in Arg132 and Arg140 2, 12 . Similarly, SRSF2 mutations were confined to the well-known Pro95 hotspot 13, 14 . TP53 mutations were primarily in the DNA-binding, transactivation and oligomerization domains 15, 16 . The distribution of mutations within functional protein domains, as well as the type of mutations found at each location, is shown in the Supplementary Information ( Supplementary  Figs. 5-8, 13-15 ). We also identified relatively few non-canonical mutations, such as non-RING domain CBL mutations, non-kinase JAK2 mutations, as well as mutations in FLT1 and CARD11. These mutations were almost always associated with the presence of probable driver comutations in DNMT3A and/or TET2 and were unique to particular study subjects. Notably, these mutations typically demonstrated persistence in the study participant when serial samples were available ( Supplementary Fig. 11 ). Although these mutations are not likely to drive the observed clonal expansions, they are likely passenger events that are symptomatic of driver mutations and thus accurately reflect the premalignant state in cases with AML and clonal hematopoiesis when present in the controls.
We next sought to derive population-based estimates of the impact of mutations in high-risk genes on AML development using a pseudolikelihood-based approach 17 . Mutation-free participants in the high-risk genes (DNMT3A, TET2, TP53, IDH1 or IDH2, spliceosome (SRSF2, SF3B1 or U2AF1)) were estimated to develop AML with an incidence of 2.7 per 100,000 per year. Mutations increased this risk at varying rates depending on the gene: TP53, 13.9 per 100,000 per year; IDH, 12.6 per 100,000 per year; spliceosome, 9.2 per 100,000 per year; DNMT3A, 4.6 per 100,000 per year; and TET2, 5.5 per 100,000 per year ( Supplementary Fig. 12 ). DNMT3A  TET2  TP53  SRSf2  IDH2  SF3B1  JAK2  ASXL1  CBL  U2AF1  PHF6  del5q  IDH1  RUNX1  del13q  del7q  Trisomy 9 Follow-up time (years) Age (years) , two-tailed Mann-Whitney U test). ***
Mutations are associated with an accelerated time to aML presentation
Cases with AML who had mutations at baseline experienced significantly shorter latency of disease than cases without baseline mutations. The presence of any mutation shifted the median time to AML diagnosis from 11.9 years (no mutations) to a median of 8.2 years after baseline assessment (P = 9.8 × 10
, log-rank test; Fig. 3a ). Univariable analysis of mutated genes demonstrated that median time to AML varied according to mutated gene (Fig. 3b) : DNMT3A (7.4 compared to 10.5 years), TP53 (4.9 compared to 10.1 years), spliceosome genes (6.7 compared to 9.9 years) and RUNX1 (1.5 compared to 9.6 years). The presence of RUNX1 mutations seemed to be associated with especially rapid development of AML within two years, but the number of participants in this subgroup was small (n = 3). Clonal complexity also affected the latency of disease as patients with one mutation in the high-risk genes developed AML in 9.1 years, but those with two or more mutations in the high-risk genes developed AML in only 6.9 years (Fig. 3c) .
Multivariable analyses produced similar findings (Fig. 2c) . Mutations in TP53 were independently associated with AML occurring within five years of baseline (odds ratio, 5.2; 95% confidence interval, 1.9-14.5; P = 0.001) as well as an increased annual rate of AML develoment (hazard ratio, 3.01; 95% confidence interval, 1.8-5.0; P = 2.8 × 10 ) when adjusted for confounding comutations and age. DNMT3A mutations when present with spliceosome mutations were also associated with increased odds of AML development within five years (odds ratio, 14.8; 95% confidence interval, 1.6-136; P = 0.02). None of the other genes were associated with increased odds of earlier AML development when present alone or with other comutations. For TP53 and DNMT3A mutations, there was no appreciable difference in time to development of AML by mutation subtype, for example, in Arg882 in DNMT3A. Finally, whereas all participants (15 out of 15) with IDH mutations were eventually diagnosed with AML, there was no increased risk of AML earlier than five years after baseline assessment, suggesting the possibility that further downstream mutational events are required for AML development in these cases.
Mutations at any VaF are associated with increased aML risk
When we considered only mutations in the genes that are associated with development of AML (high-risk genes), as shown in Fig. 4a , mutations present at VAF > 10% were found more commonly among cases compared to controls (odds ratio, 14.8; 95% confidence interval, 5.8-48.8; P = 1.5 × 10
−13
). As demonstrated in the histograms, mutations in DNMT3A and TET2 at lower VAFs were notably more distributed among cases and controls. By contrast, mutations present at higher VAFs in DNMT3A and TET2 were almost exclusively seen in cases with AML, suggesting that mutations in DNMT3A and TET2 are less specific to cases with AML at lower VAFs. In a multivariable model evaluating high (≥ 10%) and low VAFs (< 10%) in the high-risk genes and adjusting for age and other comutations, high VAFs in DNMT3A (high VAF: odds ratio, 4.8; 95% confidence interval, 1.6-14.8; P = 0.004; low VAF: odds ratio, 2.5; 95% confidence interval, 1.4-4.4; P = 0.002), TET2 (high VAF: odds ratio, 20.4; 95% confidence interval, 3.5-120.1; P = 0.002; low VAF: odds ratio, 3.6; 95% confidence interval, 1.5-8.9; P = 0.004) and spliceosome genes (high VAF: odds ratio, 14.1; 95% confidence interval, 0.8-260.9; P = 0.019, low VAF: odds ratio, 3.4; 95% confidence interval, 0.7-16.8; P = 0.105) were associated with higher odds of developing AML ( Supplementary Fig. 22 ). For TP53 and IDH mutations, the odds of AML development did not significantly change between lower and higher VAFs as all of these subjects developed AML. Next, we further examined the specificity of mutations in genes that were significantly associated with cases with AML (Fig. 1a) by determining their frequency in controls. The true-positive and false-positive rate of mutations at varying VAF cutoffs was visualized using receiver operating characteristic analysis (Fig. 4b) . Individually, mutations in TP53, SRSF2, U2AF1, SF3B1 and IDH2 produced a < 1% rate of false-positive detection at VAF cutoffs ranging from 1 to 2%. Although not exactly replicating the false-positive rate in the general population, these data provide a starting point for future studies to assess the false-positive rate in the general population. Tabulated results are available in Supplementary Fig. 9 . For the subset of participants for whom serial samples were available, changes in VAF were assessed from baseline to one or three or years. We evaluated whether the time to AML development was influenced by the fold increase in VAF in participants who had demonstrated a statistically significant increase in VAF upon serial testing (Fig. 4c) . The rate of increase in VAF for IDH2 mutations (R 2 = 0.67; slope, − 3.3; 95% confidence interval, − 21.5 to − 3.7; P = 0.02) and TP53 mutations (R 2 = 0.87; slope, − 3.0; 95% confidence interval, − 14.0 to − 5.5; P = 0.009) was significantly associated with a shorter time to AML development in a linear regression analysis. Although this relationship was similar for mutations in DNMT3A, it did not achieve statistical significance. Overall, > 95% of mutations persisted when evaluated longitudinally at one year or three years after baseline. However, there were fewer changes from baseline allelic fraction across all genes in year 1 compared to year 3 ( Supplementary Figs. 10, 11 ).
association between non-aML cancer history and mutations
We examined the mutational patterns of the 21 cases and 19 controls that had a history of malignancy at baseline, including breast, lung, bladder, endometrial, ovarian and colon cancer. Treatment history for the cancer was not known. In total, 42% of cases (n = 9 out of 21) and 26% of controls (n = 5 out of 19) with a prior history of cancer at baseline were found to have mutations (not significant). Although the absolute number of cases and controls with a prior cancer history was low, we did note that 3 out of 10 cases with a prior history of cancer had IDH2 mutations at baseline evaluation and that all three of these cases had prior breast cancer. None of the cases or controls with a prior history of cancer had TP53 gene mutations. Overall, because of the low number of cases and controls with a prior history of cancer, we did not have sufficient power to study this effect.
Progression to aML from baseline mutations
Despite having selected for participants who eventually developed AML, we noted the absence of NPM1 and FLT3 mutations, which are among the two most frequently recurring driver mutations in AML 1, 18 . This finding is consistent with other reports of their absence in clonal hematopoiesis, and suggests that they may have a cooperative role in AML pathogenesis 4, 5 . We identified a single case for whom follow-up at year 1 preceded AML diagnosis by < 30 days (Fig. 5, case A) and compared mutations at baseline and year 1 (< 30 days prior to AML diagnosis). The depth of sequencing coverage at NPM1 insertion sites was similar at both time points (around 450× ). The participant had an IDH2 mutation (8% VAF) at baseline and after one year had acquired a new NPM1 type-A mutation (14% VAF), along with an increased VAF of a mutation in IDH2 (13%). AML was diagnosed less than 30 days later. The rapid development of AML after the acquisition of an NPM1 mutation suggests cooperation with the pre-existing IDH2 clone given the similarity of their allelic fractions.
Other patterns of clonal evolution and expansion are demonstrated in representative cases B, C and D (Fig. 5) . Mutations in genes that are typically associated with clonal hematopoiesis, such as DNMT3A and TET2, were shown to generally have stable or minimally increased VAFs in follow-up. Progression to AML was often preceded by the acquisition of new mutations or by the expansion of mutations in other genes, such as RUNX1 or TP53 (Fig. 5) . With the exception of case B, who had a large DNMT3A-mutated clone with multiple subclones, comutations in the same cell formally require single cell analysis.
Discussion
Peripheral blood samples collected years before AML diagnosis enabled a unique and unprecedented opportunity to establish the existence of a genomically defined premalignant state of AML years before the development of overt disease and to determine the specific risk and time to AML development that are associated with various mutations, comutations and clone sizes. We found that study participants who eventually developed AML had higher mutational complexity at WHI baseline evaluation than age-matched controls. The presence of a mutation at baseline was associated with increased odds of developing AML. Individually, the most-significant mutations associated with increased odds of AML included those in TP53, IDH1 and IDH2, spliceosome (SRSF2, SF3B1 and U2AF1), TET2 and DNMT3A. As mutations in DNMT3A and TET2 were common in controls as well, it is important to note that both higher VAFs (> 10%) and the presence of a higher number of variants (two or more) in these genes were associated with higher risk of AML. The median time to development of AML was shorter in subjects with mutations present at baseline WHI evaluation and those participants with baseline TP53 mutations and DNMT3A comutated with spliceosome genes were more likely to develop AML within the following five years. Participants with mutations in the RUNX1 gene all developed AML within two years after baseline, but the number of cases was too low to make statistical inferences. The time to develop AML was inversely correlated with an increasing VAF for somatic mutations in TP53 and IDH2. Although having a mutation in any gene from our panel at baseline increased the risk of developing AML, we identified a set of genes with high AML penetrance, including TP53, IDH1 and IDH2, SRSF2, SF3B1 and U2AF1. Any detectable VAF in the high-penetrance genes at a sensitivity cutoff of 1% was associated with increased risk of AML. When serial samples were available, we found that a more rapid rise in the allelic fraction of IDH2 or TP53 mutations was significantly associated with a shorter time to AML development. As expected, serial samples also revealed the stepwise acquisition of mutations leading to AML. Mutations in genes commonly associated with clonal hematopoiesis, such as DNMT3A and TET2, were maintained over time, while new dominant subclones arose in genes such as NPM1, TP53, and SRSF2 preceding the development of AML. We note that the absolute rate of clonal hematopoiesis in our study was on the higher end of the reported range for controls [4] [5] [6] 19, 20 , likely in part because our study consisted of participants older than 50 years of age and was performed at relatively high non-duplicate sequencing depth with a lower 1% allelic fraction cutoff. Additionally, while there is increasing consensus around the biological definition of clonal hematopoiesis, there is no universally accepted technical definition. In general, studies have varied with respect to both the demographics of the study population and technical factors, among Number and frequency of mutations in cases with AML versus controls overall and for participants younger than 65 or at least 65 years of age.
which are the sequencing techniques used (whole-genome, wholeexome or targeted sequencing), analytical approaches, in-solution capture versus amplicon sequencing, sequencer technology, depth of coverage and allelic fraction cutoff. For example, early seminal studies that helped to establish our general understanding of the prevalence of clonal hematopoiesis mutations were performed with relatively low-coverage whole-exome sequencing with lesser sensitivity for mutations present at low allelic fractions, as well as suboptimal coverage of genes recurrently mutated in clonal hematopoiesis (for example, mutations in TET2 for which there was essentially no coverage of coding exons outside of exon 3) 4, 5 . Our study finds that > 70% of TET2 mutations in both our case and control groups outside exon 3, suggesting possibly > 3-fold underestimation of clonal hematopoiesis mutations in TET2 by previous work. Moreover, recent data 20 using high-depth error-corrected sequencing demonstrated nearly ubiquitous clonal hematopoiesis dominated by mutations in DNMT3A and TET2. Irrespective of these differences, we observe in our study significantly increased mutations in cases with AML relative to clonal hematopoiesis in the control population, a significantly shorter latency period to AML development when mutations were detected, and mutations in genes of known significance among the cases with AML, such as TP53 and IDH2, that are not found among the clonal hematopoiesis controls.
A major strength of our study is having a cohort of normal controls that was reliably followed over 10 years for outcomes, including detailed baseline demographics, medical history and laboratory data, thus providing a solid scientific base for a matched case-control analyses at the population level. A limitation to our study is that we could not perform sequencing studies of blood or bone marrow taken at the time of AML diagnosis. However, for participants with serial samples, we noted that the vast majority of mutations persist at one or three years after baseline, indicating their stability and often increasing clone size ( Supplementary Fig. 11 ). Another limitation is that because our study included only women, there is also likely to be underestimation of mutations in X-linked genes with male predominance, such as PHF6 and ZRSR2 21, 22 , as well as possible overrepresentation of mutations in DNMT3A, as has been reported previously 4 . Several commonly mutated genes in AML were absent from our study, notably FLT3 and NPM1, suggesting that the acquisition of these mutations may be later events in AML ontogeny. Although pre-existing mutations in TP53 and spliceosome genes were strongly associated with the development of AML in this study, it is well-known that these mutations are not exclusive to AML and . b, Participants with mutations in genes associated with AML versus participants with no mutations in these genes (DNMT3A, n = 69 out of 188; TET2, n = 47 out of 188; TP53, n = 21 out of 188; IDH1 or IDH2, n = 15 out of 188; spliceosome, n = 26 out of 188) in addition to RUNX1 (n = 3 out of 188). Data on RUNX1 are provided because all participants with a RUNX1 (n = 3) mutation rapidly developed AML (< 2 years) although significance was not achieved due to the few participants who had mutations in RUNX1 within the cohort. c, Cases with AML who had no mutated genes (n = 86 out of 188), one mutated gene (n = 56 out of 188), or two or more mutated genes (2+ ) (n = 46 out of 188) in significant high-risk genes associated with development of AML. Two-sided P values are shown for the log-rank test.
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Any significant mutation are also associated with other hematological malignancies and as a rare clonal hematopoiesis event in normal populations 23 . However, these data provide a strong rationale for following participants with TP53 mutations. By contrast, IDH2 Arg140 mutations are relatively more specific to AML. While it is possible that some of the participants in our study developed myelodysplastic syndrome after baseline and prior to developing AML, it should be noted that all of our cases and controls had normal baseline hematological parameters. Thus, further prospective monitoring studies will be required to confirm the specificity, or lack thereof, of these mutations in predicting AML versus other hematological disorders. Within our study, we determined that for specific genes (that is, TP53, IDH2, SF3B1, SRSF2 and U2AF1), a VAF cutoff correlating with a falsepositive fraction of less than 1% could be achieved. These estimates would be a starting point for future studies to estimate the real falsepositive fraction in a general population.
In conclusion, our study establishes the premalignant landscape of mutations preceding overt AML that is present in peripheral blood at a median of 9.6 years prior to the diagnosis of AML. In our study, all participants with TP53 and IDH mutations eventually developed AML. In comparison to the mutational landscape of de novo AML 24, 25 , our premalignant AML 'case' group demonstrated a similar frequency of mutations in genes that have high AML penetrance, especially IDH2 and TP53. DNMT3A and TET2 are accordingly overrepresented in our case cohort compared to de novo AML since most instances of these mutations do not lead to AML on a population level. Our results showing an association of high allelic fractions in DNMT3A and TET2 along with clonal complexity with a higher risk of AML is important in discriminating who would likely progress to AML. The ability to detect and identify high-risk mutations suggests that monitoring strategies for patients, as well as clinical trials of potentially preventative or disease-intercepting interventions should be considered. Indeed, molecularly targeted therapy is already available for IDH2 mutations 26 and is under development for mutations in other candidate genes found in this study including IDH1, TP53 and spliceosome genes [27] [28] [29] . Moreover, preclinical data suggest that vitamin C, in clinically achievable doses, may reverse leukemogenesis mediated by TET2 deficiency 30 . Thus, as the cost of detecting mutations declines and its use in cancer surveillance increases, the feasibility of monitoring becomes more reasonable, especially when associated with a low false-positive rate and the potential availability of therapies with favorable toxicity profiles. We propose that patients at increased risk of developing AML should be followed longitudinally in long-term monitoring studies using next-generation sequencing to further evaluate the prognostic and predictive importance of a premalignant state in this disease. Data from these studies will provide a robust rationale for clinical trials of preventative intervention strategies in populations at high risk of developing AML. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 1. Sample size
Describe how sample size was determined.
All available cases with centrally adjudicated AML diagnosis were used from the Women's Health Initiative Cohort. Controls were matched to cases on a one to one basis based on age, follow up time, sample collection, and medical history.
Data exclusions
Describe any data exclusions.
Participants with a history of myeloid disorders at baseline were excluded.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Longitudinal mutation data were compared to reference baseline and demonstrated 95% mutation rediscovery as shown in figures S10 and S11, indicating reproducibility of findings.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Participants were allocated based on diagnosis of AML as cases who were diagnosed with AML and controls who did not develop AML in the cohort.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators were blinded to case control status and clinical data during the experiments and these data were available for analyses only after genomic sequencing data was released to WHI.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
